logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Impact of COVID19 on pCPA Negotiations Starting to Emerge

August 13, 2020
-
Market Access News
-
Posted by MORSE - 3 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights

 

July 2020 Highlights:

  • 6 products completed CADTH review
  • 6 products initiated pCPA negotiations
  • 7 negotiations were completed with an LOI
  • 0 negotiations were closed without an LOI
  • 0 files were closed without negotiation

Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, negotiations are taking longer to start but those that start are being negotiated more quickly. There also appears to be a stabilization of activity across metrics as detailed below.

 

Files Under pCPA Consideration:

CADTH issued 6 new recommendations in July (24 files as of July 31).

PRODUCT INDICATION SPONSOR HTA REC’N* DATE
Vascepa
(icosapent ethyl)
Ischemic events in statin-treated patients HLS Theraputics CDR July 16
Stelara/Stelara I.V.
(ustekinumab)
Ulcerative Colitis Janssen CDR July 16
Tecentriq & Avastin
(atezolizumab & bevacizumab)
Non-Squamous Non-Small Cell Lung Cancer Hoffman-La Roche pCODR July 20
Mayzent
(siponimod)
Secondary progressive multiple sclerosis Novartis CDR July 21
Aimovig
(erenumab)
Migraine Novartis CDR July 22
Vocabria and Cabenuva
(cabotegravir sodium cabotegravir-rilpivirine)
HIV-1 Infection ViiV Heaalthcare CDR July 22

* REC’N DATE = Date of CDEC Final Recommendation (CDR), Date Notification to Implement Issued (pCODR)

 

Signals Decoded:

 

The Volume of files Under Consideration has stabilized over the last 3 months staying around the 23-24 mark. Pre-COVID, these numbers were consistently ≤ 11. The average time Under Consideration continues to climb, but still remains less than 3 months.

Negotiation Initiation:

The pCPA initiated 6 new negotiations in July (27 active negotiations as of July 31, 2020)

PRODUCT INDICATION SPONSOR CATEGORY INITIATE DATE TTI*
Darzalex SC
(daratumumab)
Multiple Myeloma Janssen Other July 10 N/A
Adcetris
(Brentuximab vedotin)
Peripheral T-Cell Lymphoma Seattle Genetics pCODR July 3 14
Lonsurf
(trifluridine/tipiracil)
Metastatic Gastric Cancer Taiho pCODR July 7 90
Dupixent
(dupilumab)
Atopic Dermatitis Sanofi Genzyme CDR July 28 97
Monoferric
(iron (iii) isomaltoside 1000)
Iron Deficiency Anemia Pharmacosmos A/S CDR July 21 118
Trintellix
(vortioxetine)
Major Depressive Disorder Lundbeck CDR July 6 145

* TTI = Time to Initiate in calendar days

 

Signals Decoded:

 

The volume of active files continues to be lower than seen pre-COVID, corresponding with the higher number of files Under Consideration. However, we see a stabilization in the numbers from May – July 2020 perhaps signalling an equilibrium in activity.

 

Of the 6 files that initiated negotiations, they were evenly split between oncology and non-oncology files. Most were under consideration for 3-5 months before being initiated with the exception of Adcetris for Peripheral T-Cell lymphoma which was initiated within 2 weeks of the Notification to Implement date.

Completed/Closed Negotiations:

The pCPA completed 7 negotiations with a Letter of Intent (LOI) in July 2020.

PRODUCT INDICATION SPONSOR LOI DATE TTN*
Kisqali
(ribociclib)
Advanced or metastatic breast cancer Novartis July 14 22
Allerject
(epinephrine)
For the emergency treatment of severe acute allergic reactions (anaphylaxis) Kaleo July 22 61
Kisqali with fulvestrant
(ribociclib)
Advanced or metastatic breast cancer Novartis July 14 64
Ziextenzo
(pegfilgrastim)
Febrile neutropenia in non-myeloid malignancies Sandoz July 22 86
Envarsus PA
(tacrolimus)
Prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients Paladin Labs July 30 136
Lutathera
(lutetium 177 dotatate)
Gastroenteropancreatic neuroendocrine tumors Advanced Accelerator Applications July 29 154
Xeljanz
(tofacitinib)
Ulcerative Colitis Pfizer July 24 385

* TTN = Time to Negotiate in calendar days

 

Signals Decoded:

 

The average duration of negotiation for currently active files time has dropped since March, with the current average sitting at 4 months compared to 5.7 months in February.

Signals Decoded:

 

The number of protracted negotiations (active more than 12 months) has decreased and is very low (from 5 to only 1) while the opposite trend is occurring with the number of files Under Consideration for extended periods (greater than 6 months) which we see increasing (from 0 to 4).

Signals Decoded:

 

Total number of adjudicated files appears to be trending back towards numbers generally seen pre-COVID.

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

 

Share
Tags
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
MORSE Consulting Bolsters Private Payer Expertise
NEXT POST →
Some Positive Indicators as Number of Files Under Consideration Remains Flat - June 2020

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Impact of COVID19 on pCPA Negotiations Starting to Emerge